Sermorelin Dosage: What the Research Reports

What is sermorelin, and how does it work?

Sermorelin is a synthetic peptide that copies the first 29 amino acids of growth hormone releasing hormone (GHRH), and it works by prompting the pituitary gland to release growth hormone the body already makes (Prakash and Goa, 1999).

GHRH is the natural signal the brain uses to tell the pituitary to release growth hormone. The active part of that signal sits in the first 29 amino acids, which is why a shortened analog can still act on the same receptor (Prakash and Goa, 1999). This differs from adding growth hormone directly, because the pituitary stays in the loop.

The same GHRH(1-29) sequence underlies other research peptides. CJC-1295 is a longer-acting analog built on that core, and Teichman et al., 2006 reported that it produced sustained increases in growth hormone and IGF-1 in study subjects. Tesamorelin is another GHRH analog studied in controlled trials (Falutz et al., 2007). Sermorelin sits at the front of this family as the shorter-acting parent sequence.

What sermorelin dosage does published research report?

Peer-reviewed, adult dose-response data specific to sermorelin is limited, and its most documented human use is historical, which is why Peptara Labs routes the exact figures and units to the prescribing information and a qualified clinician rather than printing numbers on a page.

What can be cited with confidence is how the wider GHRH-analog and GH-secretagogue class behaved in controlled research. The grid below compares those compounds and their peer-reviewed findings. It is a class comparison, not a schedule, and it does not tell you what to take.

A note on units: the cited trials for the comparators above report their own dose figures inside the source papers. Peptara Labs does not reproduce those numbers as a schedule, because a number on a page reads like instruction. A clinician can read the primary sources and the current sermorelin label with you.

Why doesn't this page list a specific sermorelin dose?

Because Peptara Labs publishes only figures it can tie to a verifiable source, and it never frames any figure as personal advice.

Two rules shape this page. First, every number needs a real citation, and sermorelin's specific figures live in its prescribing information, which a clinician can confirm is current. Second, Peptara Labs does not prescribe, so even a well-sourced number is not a recommendation to you. Sermorelin's documented human use is historical and was clinician-supervised, which is exactly the kind of decision that belongs with a prescriber rather than a web page. If you want the specific figures and units, ask a qualified clinician and bring the current label.

How does sermorelin compare with CJC-1295, tesamorelin, and other GH secretagogues?

They all aim to raise the body's own growth hormone, but they differ in how long they act, which receptor they hit, and how much human trial data backs them.

• Sermorelin and CJC-1295 both build on the GHRH(1-29) sequence. CJC-1295, especially the version with DAC, was engineered to last longer, and Teichman et al., 2006 reported sustained GH and IGF-1. Sermorelin acts on a shorter timescale, which is part of why longer-acting analogs were developed.
• Tesamorelin is a GHRH analog with controlled-trial data: in Falutz et al., 2007, it reduced visceral adipose tissue by about 15 percent.
• Ipamorelin works through a different door, the ghrelin-receptor pathway, and Raun et al., 1998 characterized it as a selective GH secretagogue, meaning it raised GH with less spillover onto other hormones in that early work.
• MK-677 (ibutamoren) is an oral ghrelin mimetic. It is not injected, but Nass et al., 2008 reported it raised fasting glucose and lowered insulin sensitivity, a metabolic trade-off worth knowing.

The short version: sermorelin is the short-acting GHRH parent, CJC-1295 is the long-acting relative, tesamorelin is the analog with the clearest body-composition trial signal, and the ghrelin-pathway compounds behave differently and carry their own metabolic notes.

What safety signals show up in the research?

The clearest cited safety signal in this class is metabolic: the oral GH secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity in a controlled study (Nass et al., 2008), which is one reason clinicians watch GH-axis compounds.

Growth-hormone signaling touches glucose handling, fluid balance, and IGF-1 levels, so any compound that pushes that axis can move those markers. Long-term, adult-specific safety data for sermorelin itself is limited, so the responsible read is caution plus clinician oversight rather than assumption. This is not a claim that sermorelin is safe or unsafe for you; it is a summary of what the cited research shows and does not show.